Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Inflammatory Bowel Diseases

  Free Subscription


23.10.2017

2 Aliment Pharmacol Ther
2 Am J Gastroenterol
1 Dig Dis
4 Dig Dis Sci
1 Dis Colon Rectum
4 Gut
2 Inflamm Bowel Dis
20 J Crohns Colitis
1 J Gastroenterol
1 J Pediatr
2 Lancet
4 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Aliment Pharmacol Ther

  1. KUMP P, Wurm P, Grochenig HP, Wenzl H, et al
    The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Oct 20. doi: 10.1111/apt.14387.
    PubMed     Text format     Abstract available

  2. MCILROY J, Ianiro G, Mukhopadhya I, Hansen R, et al
    Review article: the gut microbiome in inflammatory bowel disease-avenues for microbial management.
    Aliment Pharmacol Ther. 2017 Oct 16. doi: 10.1111/apt.14384.
    PubMed     Text format     Abstract available


    Am J Gastroenterol

  3. BUCHNER AM, Lichtenstein GR
    Editorial: Endoscopic Scoring Systems in Crohn's Disease for Evaluation of Responsiveness to Treatment: Are we Ready for the Prime Time of Endoscopic Assessment?
    Am J Gastroenterol. 2017;112:1593-1595.
    PubMed     Text format     Abstract available

  4. KHANNA R, Zou G, Stitt L, Feagan BG, et al
    Responsiveness of Endoscopic Indices of Disease Activity for Crohn's Disease.
    Am J Gastroenterol. 2017;112:1584-1592.
    PubMed     Text format     Abstract available


    Dig Dis

  5. TAKEUCHI K, Shimoyama T, Yamamoto T
    Comparison of Safety and Efficacy of Tacrolimus versus Infliximab for Active Ulcerative Colitis.
    Dig Dis. 2017 Oct 19. doi: 10.1159/000481815.
    PubMed     Text format     Abstract available


    Dig Dis Sci

  6. DIETRICH C, Singh SR
    Circulating Endothelial Progenitor Cells in Crohn's Disease: An EPiC in the Making?
    Dig Dis Sci. 2017;62:567-568.
    PubMed     Text format    

  7. DAI C, Jiang M, Sun MJ
    Fecal Calprotectin in Monitoring the Disease Activity in Colonic Inflammatory Bowel Disease.
    Dig Dis Sci. 2017 Oct 17. doi: 10.1007/s10620-017-4799.
    PubMed     Text format    

  8. CALLOWAY A, Dalal R, Beaulieu DB, Duley C, et al
    Depressive Symptoms Predict Anti-tumor Necrosis Factor Therapy Noncompliance in Patients with Inflammatory Bowel Disease.
    Dig Dis Sci. 2017 Oct 20. doi: 10.1007/s10620-017-4800.
    PubMed     Text format     Abstract available

  9. CAMPBELL JP, Burton E, Wymer S, Shaw M, et al
    Out-of-Pocket Cost Is a Barrier to Therapeutic Drug Monitoring in Inflammatory Bowel Disease.
    Dig Dis Sci. 2017 Oct 20. doi: 10.1007/s10620-017-4808.
    PubMed     Text format     Abstract available


    Dis Colon Rectum

  10. LIGHTNER AL, Fletcher JG, Pemberton JH, Mathis KL, et al
    Crohn's Disease of the Pouch: A True Diagnosis or an Oversubscribed Diagnosis of Exclusion?
    Dis Colon Rectum. 2017;60:1201-1208.
    PubMed     Text format     Abstract available


    Gut

  11. KIM HS, Cheon JH, Jung ES, Park J, et al
    A coding variant in FTO confers susceptibility to thiopurine-induced leukopenia in East Asian patients with IBD.
    Gut. 2017;66:1926-1935.
    PubMed     Text format     Abstract available

  12. ZUNDLER S, Schillinger D, Fischer A, Atreya R, et al
    Blockade of alphaEbeta7 integrin suppresses accumulation of CD8+ and Th9 lymphocytes from patients with IBD in the inflamed gut in vivo.
    Gut. 2017;66:1936-1948.
    PubMed     Text format     Abstract available

  13. ALLEZ M, Skolnick BE, Wisniewska-Jarosinska M, Petryka R, et al
    Anti-NKG2D monoclonal antibody (NNC0142-0002) in active Crohn's disease: a randomised controlled trial.
    Gut. 2017;66:1918-1925.
    PubMed     Text format     Abstract available

  14. HOCHART A, Gower-Rousseau C, Sarter H, Fumery M, et al
    Ulcerative proctitis is a frequent location of paediatric-onset UC and not a minor disease: a population-based study.
    Gut. 2017;66:1912-1917.
    PubMed     Text format     Abstract available


    Inflamm Bowel Dis

  15. HOPKINS CWP
    Inflammatory Bowel Disease, the Hospital Anxiety and Depression Scale and Criterion Contamination.
    Inflamm Bowel Dis. 2017;23:E54.
    PubMed     Text format    

  16. SHIBATA W, Sohara M, Wu R, Kobayashi K, et al
    Incidence and Outcomes of Central Venous Catheter-related Blood Stream Infection in Patients with Inflammatory Bowel Disease in Routine Clinical Practice Setting.
    Inflamm Bowel Dis. 2017;23:2042-2047.
    PubMed     Text format     Abstract available


    J Crohns Colitis

  17. REINISCH W, Colombel JF, D'Haens G, Sandborn WJ, et al
    Characterisation of Mucosal Healing with Adalimumab Treatment in Patients with Moderately to Severely Active Crohn's Disease: Results from the EXTEND Trial.
    J Crohns Colitis. 2017;11:425-434.
    PubMed     Text format     Abstract available

  18. DIAS CC, Rodrigues PP, Coelho R, Santos PM, et al
    Development and Validation of Risk Matrices for Crohn's Disease Outcomes in Patients Who Underwent Early Therapeutic Interventions.
    J Crohns Colitis. 2017;11:445-453.
    PubMed     Text format     Abstract available

  19. BOJIC D, Bodger K, Travis S
    Patient Reported Outcome Measures (PROMs) in Inflammatory Bowel Disease: New Data.
    J Crohns Colitis. 2017;11.
    PubMed     Text format     Abstract available

  20. SCHOLMERICH J, Fellermann K, Seibold FW, Rogler G, et al
    A Randomised, Double-blind, Placebo-controlled Trial of Trichuris suis ova in Active Crohn's Disease.
    J Crohns Colitis. 2017;11:390-399.
    PubMed     Text format     Abstract available

  21. ARSONIADIS EG, Ho YY, Melton GB, Madoff RD, et al
    African Americans and Short-Term Outcomes after Surgery for Crohn's Disease: An ACS-NSQIP Analysis.
    J Crohns Colitis. 2017;11:468-473.
    PubMed     Text format     Abstract available

  22. ALEXAKIS C, Gordon K, Mellor R, Chong H, et al
    Ano-genital Granulomatosis and Crohn's Disease: A Case Series of Males Presenting with Genital Lymphoedema.
    J Crohns Colitis. 2017;11:454-459.
    PubMed     Text format     Abstract available

  23. MAGRO F, Lopes S, Coelho R, Cotter J, et al
    Accuracy of Faecal Calprotectin and Neutrophil Gelatinase B-associated Lipocalin in Evaluating Subclinical Inflammation in UlceRaTIVE Colitis-the ACERTIVE study.
    J Crohns Colitis. 2017;11:435-444.
    PubMed     Text format     Abstract available

  24. DING YP, Ladeiro Y, Morilla I, Bouhnik Y, et al
    Integrative Network-based Analysis of Colonic Detoxification Gene Expression in Ulcerative Colitis According to Smoking Status.
    J Crohns Colitis. 2017;11:474-484.
    PubMed     Text format     Abstract available

  25. LOFTUS EV JR, Colombel JF, Feagan BG, Vermeire S, et al
    Long-term Efficacy of Vedolizumab for Ulcerative Colitis.
    J Crohns Colitis. 2017;11:400-411.
    PubMed     Text format     Abstract available

  26. VERMEIRE S, Loftus EV Jr, Colombel JF, Feagan BG, et al
    Long-term Efficacy of Vedolizumab for Crohn's Disease.
    J Crohns Colitis. 2017;11:412-424.
    PubMed     Text format     Abstract available

  27. SMIDS C, Horjus Talabur Horje CS, van Wijk F, van Lochem EG, et al
    The Complexity of alpha E beta 7 Blockade in Inflammatory Bowel Diseases.
    J Crohns Colitis. 2017;11:500-508.
    PubMed     Text format     Abstract available

  28. VILLANACCI V, Baert F, Cornillie F, De Hertogh G, et al
    Challenges Faced by Cross-sectional Imaging and Histological Endpoints in Clinical Trials.
    J Crohns Colitis. 2017;11.
    PubMed     Text format     Abstract available

  29. GUIRGIS M, Wendt E, Wang LM, Walsh A, et al
    Beyond Histological Remission: Intramucosal Calprotectin as a Potential Predictor of Outcomes in Ulcerative Colitis.
    J Crohns Colitis. 2017;11:460-467.
    PubMed     Text format     Abstract available

  30. PANES J, Vermeire S, Lindsay JO, Sands BE, et al
    Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomized Controlled Induction and Maintenance Studies.
    J Crohns Colitis. 2017 Sep 27. doi: 10.1093.
    PubMed     Text format     Abstract available

  31. VANHOVE W, Nys K, Arijs I, Cleynen I, et al
    Biopsy-derived intestinal epithelial cell cultures for pathway based stratification of patients with inflammatory bowel disease.
    J Crohns Colitis. 2017 Sep 23. doi: 10.1093.
    PubMed     Text format     Abstract available

  32. DEDERICHS F, Iesalnieks I, Sladek M, Tzivinikos C, et al
    Genital granulomatosis in male and female patients with Crohn`s disease: clinical presentation and treatment outcomes.
    J Crohns Colitis. 2017 Sep 27. doi: 10.1093.
    PubMed     Text format     Abstract available

  33. ANIWAN S, Tremaine WJ, Raffals LE, Kane SV, et al
    Antibiotic use and new-onset inflammatory bowel disease in Olmsted County, Minnesota: a population-based case-control study.
    J Crohns Colitis. 2017 Sep 28. doi: 10.1093.
    PubMed     Text format     Abstract available

  34. NORDENVALL C, Rosvall O, Bottai M, Everhov AH, et al
    Surgical treatment in childhood-onset inflammatory bowel disease -A nationwide register-based study of 4,695 incident patients in Sweden 2002-2014.
    J Crohns Colitis. 2017 Sep 27. doi: 10.1093.
    PubMed     Text format     Abstract available

  35. TAMAN H, Fenton CG, Hensel IV, Anderssen E, et al
    Transcriptomic Landscape of Treatment - Naive Ulcerative Colitis.
    J Crohns Colitis. 2017 Oct 10. doi: 10.1093.
    PubMed     Text format     Abstract available

  36. MIKOCKA-WALUS A, Hughes PA, Bampton P, Gordon A, et al
    Fluoxetine for Maintenance of Remission and to Improve Quality of Life in Patients with Crohn's Disease: a Pilot Randomized Placebo-Controlled Trial.
    J Crohns Colitis. 2017;11:509-514.
    PubMed     Text format     Abstract available


    J Gastroenterol

  37. NAGANUMA M, Aoyama N, Tada T, Kobayashi K, et al
    Correction to: Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study.
    J Gastroenterol. 2017 Oct 13. doi: 10.1007/s00535-017-1399.
    PubMed     Text format     Abstract available


    J Pediatr

  38. BARNES EL, Kochar B, Long MD, Martin CF, et al
    The Burden of Hospital Readmissions among Pediatric Patients with Inflammatory Bowel Disease.
    J Pediatr. 2017 Oct 13. pii: S0022-3476(17)31102.
    PubMed     Text format     Abstract available


    Lancet

  39. NG SC, Shi HY, Hamidi N, Underwood FE, et al
    Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies.
    Lancet. 2017 Oct 13. pii: S0140-6736(17)32448.
    PubMed     Text format     Abstract available

  40. KAMM MA
    Rapid changes in epidemiology of inflammatory bowel disease.
    Lancet. 2017 Oct 13. pii: S0140-6736(17)32669.
    PubMed     Text format    


    PLoS One

  41. PERRY T, Laffin M, Fedorak RN, Thiesen A, et al
    Ileocolic resection is associated with increased susceptibility to injury in a murine model of colitis.
    PLoS One. 2017;12:e0184660.
    PubMed     Text format     Abstract available

  42. SJOBERG F, Barkman C, Nookaew I, Ostman S, et al
    Low-complexity microbiota in the duodenum of children with newly diagnosed ulcerative colitis.
    PLoS One. 2017;12:e0186178.
    PubMed     Text format     Abstract available

  43. MORTENSEN JH, Manon-Jensen T, Jensen MD, Hagglund P, et al
    Ulcerative colitis, Crohn's disease, and irritable bowel syndrome have different profiles of extracellular matrix turnover, which also reflects disease activity in Crohn's disease.
    PLoS One. 2017;12:e0185855.
    PubMed     Text format     Abstract available

  44. CHEN L, Zhou Z, Yang Y, Chen N, et al
    Therapeutic effect of imiquimod on dextran sulfate sodium-induced ulcerative colitis in mice.
    PLoS One. 2017;12:e0186138.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: